Mizuho Maintains Outperform on Arcutis Biotherapeutics, Lowers Price Target to $35
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Mizuho analyst Uy Ear maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Outperform and lowers the price target from $37 to $35.
Mizuho analyst Uy Ear maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Outperform and lowers the price target from $37 to $35.